Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Amgen Dividend Announcement
• Amgen announced a quarterly dividend of $2.25 per ordinary share which will be made payable on 2024-12-09. Ex dividend date: 2024-11-18
• Amgen annual dividend for 2024 was $9.00
• Amgen annual dividend for 2023 was $8.52
• Amgen's trailing twelve-month (TTM) dividend yield is 2.76%
• Amgen's payout ratio for the trailing twelve months (TTM) is 112.70%
• Amgen's dividend growth over the last five years (2018-2023) was 10.04% year
• Amgen's dividend growth over the last ten years (2013-2023) was 16.31% year
Amgen Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-11-18 | $2.25 | quarterly | 2024-12-09 |
2024-08-16 | $2.25 | quarterly | 2024-09-06 |
2024-05-16 | $2.25 | quarterly | 2024-06-07 |
2024-02-15 | $2.25 | quarterly | 2024-03-07 |
2023-11-16 | $2.13 | quarterly | 2023-12-08 |
2023-08-17 | $2.13 | quarterly | 2023-09-08 |
2023-05-17 | $2.13 | quarterly | 2023-06-08 |
2023-02-14 | $2.13 | quarterly | 2023-03-08 |
2022-11-16 | $1.94 | quarterly | 2022-12-08 |
2022-08-17 | $1.94 | quarterly | 2022-09-08 |
2022-05-16 | $1.94 | quarterly | 2022-06-08 |
2022-02-14 | $1.94 | quarterly | 2022-03-08 |
2021-11-15 | $1.76 | quarterly | 2021-12-08 |
2021-08-16 | $1.76 | quarterly | 2021-09-08 |
2021-05-14 | $1.76 | quarterly | 2021-06-08 |
2021-02-11 | $1.76 | quarterly | 2021-03-08 |
2020-11-13 | $1.60 | quarterly | 2020-12-08 |
2020-08-14 | $1.60 | quarterly | 2020-09-08 |
2020-05-15 | $1.60 | quarterly | 2020-06-08 |
2020-02-13 | $1.60 | quarterly | 2020-03-06 |
2019-11-14 | $1.45 | quarterly | 2019-12-06 |
2019-08-14 | $1.45 | quarterly | 2019-09-06 |
2019-05-16 | $1.45 | quarterly | 2019-06-07 |
2019-02-14 | $1.45 | quarterly | 2019-03-08 |
2018-11-15 | $1.32 | quarterly | 2018-12-07 |
2018-08-16 | $1.32 | quarterly | 2018-09-07 |
2018-05-16 | $1.32 | quarterly | 2018-06-08 |
2018-02-14 | $1.32 | quarterly | 2018-03-08 |
2017-11-16 | $1.15 | quarterly | 2017-12-08 |
2017-08-15 | $1.15 | quarterly | 2017-09-08 |
2017-05-15 | $1.15 | quarterly | 2017-06-08 |
2017-02-13 | $1.15 | quarterly | 2017-03-08 |
2016-11-14 | $1.00 | quarterly | 2016-12-08 |
2016-08-15 | $1.00 | quarterly | 2016-09-08 |
2016-05-13 | $1.00 | quarterly | 2016-06-08 |
2016-02-11 | $1.00 | quarterly | 2016-03-08 |
2015-11-12 | $0.79 | quarterly | 2015-12-07 |
2015-08-13 | $0.79 | quarterly | 2015-09-08 |
2015-05-12 | $0.79 | quarterly | 2015-06-05 |
2015-02-10 | $0.79 | quarterly | 2015-03-06 |
2014-11-10 | $0.61 | quarterly | 2014-12-05 |
2014-08-12 | $0.61 | quarterly | 2014-09-05 |
2014-05-13 | $0.61 | quarterly | 2014-06-06 |
2014-02-11 | $0.61 | quarterly | 2014-03-07 |
2013-11-12 | $0.47 | quarterly | 2013-12-06 |
2013-08-14 | $0.47 | quarterly | 2013-09-06 |
2013-05-14 | $0.47 | quarterly | 2013-06-07 |
2013-02-11 | $0.47 | quarterly | 2013-03-07 |
Amgen Dividend per year
Amgen Dividend growth
Amgen Dividend Yield
Amgen current trailing twelve-month (TTM) dividend yield is 2.76%. Interested in purchasing Amgen stock? Use our calculator to estimate your expected dividend yield:
Amgen Financial Ratios
Amgen Dividend FAQ
Other factors to consider when evaluating Amgen as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Amgen stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Amgen's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Amgen publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Amgen distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Amgen are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Amgen sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Amgen distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Amgen declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Amgen's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Amgen's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.